ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026
Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug-Resistance Uropathogenic
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug-Resistance UropathogenicThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There are limited therapeutic options available for treating aminoglycoside- and carbapenem-resistant Gram-negative bacteria. Therefore, there is an urgent need for novel effective antimicrobial agents. Numerous studies have reported the enhanced efficacy of antibiotic combinations against multidrug-resistant (MDR) strains compared to monotherapy. This study aimed to investigate the potential synergistic effects of amikacin in combination with imipenem and ciprofloxacin against clinical isolates of MDR Methods: In this experimental study, 20 MDR Results: MIC determination revealed ciprofloxacin MICs of 4-512 μg/mL, imipenem 0.125-32 μg/mL, and amikacin 1-128 μg/mL. Resistance rates were 55% (11/20) for amikacin, 100% (20/20) for ciprofloxacin, and 55% (11/20) for imipenem. Synergistic effects were observed between amikacin and imipenem in 50% of isolates (10/20) and between amikacin and ciprofloxacin in 40% (8/20), with no antagonistic interactions detected. Conclusions: The combination of amikacin with imipenem or ciprofloxacin resulted in synergistic and additive effects in some cases. These findings suggest that antibiotic combination therapy could serve as an effective strategy in managing infections caused by antibiotic-resistant isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.